ArticleMetabolites2023
Metabolic Signatures Elucidate the Effect of Body Mass Index on Type 2 Diabetes.
Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Metabolomics profile in diabetes and blood glucose regulation: a systematic review.Frontiers in nutrition · 2026Pooled it
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Serum metabolite patterns of adipose tissue distribution and body composition subphenotypes.Lipids in health and disease · 2026Article
- Plasma Metabolite Associations for Risk and Laboratory Measures of Type 2 Diabetes in a Large-Scale Finnish Prospective Cohort.Diabetes care · 2026Article
- Integrated genomics and metabolomics to identify cause-specific biomarkers for chronic kidney disease in a Korean population.Kidney research and clinical practice · 2026Article
- Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus.Cardiovascular diabetology · 2025Article
- Serum metabolites characterize hepatic phenotypes and reveal shared pathways: results from population-based imaging.Molecular medicine (Cambridge, Mass.) · 2025Article
- Role of major cardiovascular surgery-induced metabolic reprogramming in acute kidney injury in critical care.Intensive care medicine · 2025Observational
- Role of human plasma metabolites in prediabetes and type 2 diabetes from the IMI-DIRECT study.Diabetologia · 2024Article
- Preliminary investigations of plasma lipidome and selenium levels in adults with treated hypothyroidism and in healthy individuals without selenium deficiency.Scientific reports · 2024Article
- Application of Human Plasma Targeted Lipidomics and Analysis of Toxic Elements to Capture the Metabolic Complexities of Hypothyroidism.Molecules (Basel, Switzerland) · 2024Article
- Article
- Circulating Selenium Level Was Positively Related to Visceral Adiposity Index with a Non-linear Trend: a Nationwide Study of the General Population.Biological trace element research · 2024Article
- Lipids as potential mediators linking body mass index to diabetes: evidence from a mediation analysis based on the NAGALA cohort.BMC endocrine disorders · 2024Article
- The Circulating Selenium Concentration Is Positively Related to the Lipid Accumulation Product: A Population-Based Cross-Sectional Study.Nutrients · 2024Article
- Serum metabolite signatures of cardiac function and morphology in individuals from a population-based cohort.Biomarker research · 2024Article
- Metabolomic associations of impaired awareness of hypoglycaemia in type 1 diabetes.Scientific reports · 2024Article
- Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease.Cardiovascular diabetology · 2024Article
- Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors.World journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity plays an important role in the development of insulin resistance and diabetes, but the molecular mechanism that links obesity and diabetes is still not completely understood. Here, we used 146 targeted metabolomic profiles from the German KORA FF4 cohort consisting of 1715 participants and associated them with obesity and type 2 diabetes. In the basic model, 83 and 51 metabolites were significantly associated with body mass index (BMI) and T2D, respectively. Those metabolites are branched-chain amino acids, acylcarnitines, lysophospholipids, or phosphatidylcholines. In the full model, 42 and 3 metabolites were significantly associated with BMI and T2D, respectively, and replicate findings in the previous studies. Sobel mediation testing suggests that the effect of BMI on T2D might be mediated via lipids such as sphingomyelin (SM) C16:1, SM C18:1 and diacylphosphatidylcholine (PC aa) C38:3. Moreover, mendelian randomization suggests a causal relationship that BMI causes the change of SM C16:1 and PC aa C38:3, and the change of SM C16:1, SM C18:1, and PC aa C38:3 contribute to T2D incident. Biological pathway analysis in combination with genetics and mice experiments indicate that downregulation of sphingolipid or upregulation of phosphatidylcholine metabolism is a causal factor in early-stage T2D pathophysiology. Our findings indicate that metabolites like SM C16:1, SM C18:1, and PC aa C38:3 mediate the effect of BMI on T2D and elucidate their role in obesity related T2D pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.